{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:24:40Z","timestamp":1776119080576,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2008,4,19]],"date-time":"2008-04-19T00:00:00Z","timestamp":1208563200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s11010-008-9772-y","type":"journal-article","created":{"date-parts":[[2008,4,18]],"date-time":"2008-04-18T13:19:16Z","timestamp":1208524756000},"page":"123-131","source":"Crossref","is-referenced-by-count":41,"title":["Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats"],"prefix":"10.1007","volume":"314","author":[{"given":"Bhoomika R.","family":"Goyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin","family":"Mesariya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh K.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,19]]},"reference":[{"key":"9772_CR1","doi-asserted-by":"crossref","first-page":"30T","DOI":"10.1016\/S0002-9149(98)00720-6","volume":"82","author":"HC McGill Jr","year":"1998","unstructured":"McGill HC Jr, McMahan CA (1998) Determinants of atherosclerosis in the young: pathobiological determinants of atherosclerosis in youth (PDAY) research group. Am J Cardiol 82:30T\u201336T","journal-title":"Am J Cardiol"},{"issue":"4","key":"9772_CR2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1210\/er.2003-0012","volume":"25","author":"YF Zhi","year":"2004","unstructured":"Zhi YF, Johannes BP, Marwick JH (2004) Diabetic cardiomyopathy: evidences, mechanism and therapeutic implications. Endocr Rev 25(4):543\u2013567","journal-title":"Endocr Rev"},{"key":"9772_CR3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2337\/diacare.25.1.134","volume":"25","author":"C Arauz-Pacheco","year":"2002","unstructured":"Arauz-Pacheco C, Parrott MA, Raskin P (2002) The treatment of hypertension in adult patients with diabetes. Diabetes Care 25:134\u2013147","journal-title":"Diabetes Care"},{"key":"9772_CR4","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1161\/01.CIR.101.17.2060","volume":"101","author":"J Higaki","year":"2000","unstructured":"Higaki J, Baba S, Katsuya T, Katsuya T, Sato N, Ishikawa K, Mannami T, Ogata J, Ogihara T (2000) Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men. The Suita study. Circulation 101:2060\u20132065","journal-title":"Circulation"},{"key":"9772_CR5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","volume":"355","author":"M Burnier","year":"2000","unstructured":"Burnier M, Brunner HR (2000) Angiotensin II receptor antagonists. Lancet 355:637\u2013645","journal-title":"Lancet"},{"key":"9772_CR6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-0115(01)00246-4","volume":"99","author":"M Stoll","year":"2001","unstructured":"Stoll M, Unger T (2001) Angiotensin and its AT2 receptor: new insights into an old system. Regul Pept 99:175\u2013182","journal-title":"Regul Pept"},{"key":"9772_CR7","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0895-7061(02)02280-X","volume":"15","author":"HM Siragy","year":"2002","unstructured":"Siragy HM (2002) Angiotensin receptor blockers: how important is selectivity? Am J Hypertens 15:1006\u20131014","journal-title":"Am J Hypertens"},{"key":"9772_CR8","doi-asserted-by":"crossref","unstructured":"Benedict CR, Francis GS, Shelton B et\u00a0al for the SOLVD Investigators (1995) Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol 75:1151\u20131157","DOI":"10.1016\/S0002-9149(99)80748-6"},{"key":"9772_CR9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","volume":"16","author":"AD Struthers","year":"1995","unstructured":"Struthers AD (1995) Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 16:103\u2013106","journal-title":"Eur Heart J"},{"key":"9772_CR10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ahj.2004.04.037","volume":"148","author":"SE Kjeldsen","year":"2004","unstructured":"Kjeldsen SE, Julius S (2004) Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 148:747\u2013754","journal-title":"Am Heart J"},{"issue":"1","key":"9772_CR11","first-page":"41","volume":"25","author":"H Kakuta","year":"2005","unstructured":"Kakuta H, Sudoh K, Sasamatsu M, Yamagishi S (2005) Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor blockers. Int J Clin Pharm Res 25(1):41\u201346","journal-title":"Int J Clin Pharm Res"},{"key":"9772_CR12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","volume":"43","author":"SC Benson","year":"2004","unstructured":"Benson SC, Pershadsingh HA, Ho C, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR\u03b3\u2014modulating activity. Hypertension 43:993\u20131002","journal-title":"Hypertension"},{"key":"9772_CR13","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.2174\/1381612043383719","volume":"10","author":"H Takano","year":"2004","unstructured":"Takano H, Hasegawa H, Zou Y, Komuro I (2004) Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 10:2779\u20132786","journal-title":"Curr Pharm Des"},{"issue":"5","key":"9772_CR14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1586\/14779072.4.5.615","volume":"4","author":"M Goebel","year":"2006","unstructured":"Goebel M, Clemenz M, Unger T (2006) Effective treatment of hypertension by AT 1 receptor antagonism: the past and future of telmisartan. Expert Rev Cardiovasc Ther 4(5):615\u2013620","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"9772_CR15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.mehy.2004.09.015","volume":"64","author":"S Yamagishi","year":"2005","unstructured":"Yamagishi S, Takeuchi M (2005) Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-g-inducing property. Med Hypotheses 64:476\u2013478","journal-title":"Med Hypotheses"},{"issue":"3","key":"9772_CR16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0003-2697(60)90050-6","volume":"1","author":"DJ Prockop","year":"1960","unstructured":"Prockop DJ, Udenfriend S (1960) A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1(3):228\u2013239","journal-title":"Anal Biochem"},{"issue":"3","key":"9772_CR17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1081\/CEH-120003201","volume":"24","author":"DN Umrani","year":"2002","unstructured":"Umrani DN, Goyal RK (2002) Beneficial effects of fenoldopam treatment on renal functions in streptozotocin induced diabetic rats. Clin Exp Hypertens 24(3):207\u2013219","journal-title":"Clin Exp Hypertens"},{"key":"9772_CR18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10641969909068659","volume":"21","author":"RK Goyal","year":"1999","unstructured":"Goyal RK (1999) Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Clin Exp Hypertens 21:167\u2013179","journal-title":"Clin Exp Hypertens"},{"key":"9772_CR19","unstructured":"Pershadsingh HA, Benson SC, Ho CI, Avery MA, Kurtz TW (2003) Identification of PPAR-activators that do not promote fluid retention and edema: implications for treating insulin resistant hypertension and the metabolic syndrome. In: Proceedings of the endocrine society symposium on nuclear receptors in cardiovascular disease, hot topics in endocrinology. San Diego, CA, Abstract 29"},{"key":"9772_CR20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.hjh.0000160198.05416.72","volume":"23","author":"K Dahm","year":"2005","unstructured":"Dahm K, Tikellis C, Reid CM, Johnston CI, Cooper ME (2005) Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23:463\u2013473","journal-title":"J Hypertens"},{"key":"9772_CR21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2337\/diab.41.2.S12","volume":"41","author":"M Taskinen","year":"1992","unstructured":"Taskinen M (1992) Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 41:12\u201317","journal-title":"Diabetes"},{"key":"9772_CR22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0021-9150(93)90084-8","volume":"102","author":"A Bowie","year":"1993","unstructured":"Bowie A, Owens D, Collins P, Johnson A, Tomkin GH (1993) Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 102:63\u201367","journal-title":"Atherosclerosis"},{"key":"9772_CR23","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1161\/01.RES.84.9.1043","volume":"84","author":"DY Li","year":"1999","unstructured":"Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL (1999) Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 84:1043\u20131049","journal-title":"Circ Res"},{"key":"9772_CR24","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1006\/bbrc.2000.3532","volume":"276","author":"H Chen","year":"2000","unstructured":"Chen H, Li D, Sawamura T, Inoue K, Mehta JL (2000) Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun 276:1100\u20131104","journal-title":"Biochem Biophys Res Commun"},{"key":"9772_CR25","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.100.9.899","volume":"100","author":"H Morawietz","year":"1999","unstructured":"Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, Holtz J (1999) Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 100:899\u2013902","journal-title":"Circulation"},{"key":"9772_CR26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0002-8703(87)90511-4","volume":"114","author":"WB Kannel","year":"1987","unstructured":"Kannel WB (1987) Metabolic risk factors for coronary heart disease in women. Perspective from the Framingham study. Am Heart J 114:413\u2013419","journal-title":"Am Heart J"},{"key":"9772_CR27","first-page":"413","volume":"287","author":"WP Castelli","year":"1986","unstructured":"Castelli WP (1986) The triglyceride issue: a view from Framingham. Am Heart J 287:413\u2013419","journal-title":"Am Heart J"},{"key":"9772_CR28","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1161\/01.ATV.19.10.2348","volume":"19","author":"S Bhakdi","year":"1999","unstructured":"Bhakdi S, Toprzewski M, Klouche M, Hemmes M (1999) Complement and atherogenesis. Binding of CRP to degraded, nonoxidised LDL enhance complement activation. Arterioscler Thromb Vasc Biol 19:2348\u20132354","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9772_CR29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/hrt.47.3.239","volume":"47","author":"FC Beer de","year":"1982","unstructured":"de Beer FC, Hind CRK, Fox KM, Allan R, Maseri A, Pepys MB (1982) Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 47:239\u2013243","journal-title":"Br Heart J"},{"key":"9772_CR30","unstructured":"Rani SH, Rao DV, Prakash SM, Jyothy A (2003) Serum Adenosine deaminase activity and C-reactive protein levels in unstable angina. Indian J Human Genet 9(1):17\u201320"},{"key":"9772_CR31","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.2337\/diabetes.53.10.2569","volume":"53","author":"HP Chase","year":"2004","unstructured":"Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, Eisenbarth GS, Rewers M (2004) Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes 53:2569\u20132573","journal-title":"Diabetes"},{"key":"9772_CR32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","volume":"286","author":"A Pradhan","year":"2001","unstructured":"Pradhan A, Manson J, Rifai N, Buring J, Ridker P (2001) C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 286:327\u2013334","journal-title":"JAMA"},{"key":"9772_CR33","doi-asserted-by":"crossref","unstructured":"Yoshida S, Yamsgishi K, Nakamura T, Matsui T, Imaizumi M, Takeuchi H, Koga T, Ueno, Sata M (2006) Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferators activated receptor-\u03b3 activation. Diabetologia 49(11):3094\u20133099","DOI":"10.1007\/s00125-006-0437-7"},{"issue":"6","key":"9772_CR34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/bja\/ael303","volume":"97","author":"GM Howard-Alpe","year":"2006","unstructured":"Howard-Alpe GM, Sear JW, Foex P (2006) Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers. Brit J Anaesth 97(6):758\u2013769","journal-title":"Brit J Anaesth"},{"issue":"1\u20132","key":"9772_CR35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cca.2005.10.025","volume":"366","author":"E Huang","year":"2006","unstructured":"Huang E, Kuo W, Chen Y, Chen T, Chang M, Lu M, Tzang B, Hsu H, Huang C, Lee S (2006) Homocysteine and other biochemical parameters in type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clinica Himica Acta 366(1\u20132):293\u2013298","journal-title":"Clinica Himica Acta"},{"issue":"3","key":"9772_CR36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1043-6618(02)00095-6","volume":"46","author":"HH Hagar","year":"2002","unstructured":"Hagar HH (2002) Folic acid and vitamin B12 supplementation attenuates isoprenaline-induced myocardial infarction in experimental hyperhomocysteinemic rats. Pharmacol Res 46(3):213\u2013219","journal-title":"Pharmacol Res"},{"key":"9772_CR37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2337\/diab.25.7.604","volume":"25","author":"JR Williamson","year":"1976","unstructured":"Williamson JR, Kilo C (1976) Capillary basement membrane thickening and diabetic microangiopathy. Diabetes 25:925\u2013927","journal-title":"Diabetes"},{"key":"9772_CR38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2337\/diacare.2.2.120","volume":"2","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL (1979) Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2:120\u2013126","journal-title":"Diabetes Care"},{"key":"9772_CR39","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.101.8.899","volume":"101","author":"K Mizushige","year":"2000","unstructured":"Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101:899\u2013907","journal-title":"Circulation"},{"key":"9772_CR40","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/hc1102.105289","volume":"105","author":"MR Zile","year":"2002","unstructured":"Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105:1387\u20131393","journal-title":"Circulation"},{"key":"9772_CR41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0002-9149(99)80485-8","volume":"76","author":"CG Brilla","year":"1995","unstructured":"Brilla CG, Zhou G, Rupp H, Maisch B, Weber KT (1995) Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol 76:80\u2013130","journal-title":"Am J Cardiol"},{"issue":"6","key":"9772_CR42","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.yjmcc.2006.07.019","volume":"41","author":"H Takenaka","year":"2006","unstructured":"Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, Kita T (2006) Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol 41(6):989\u2013997","journal-title":"J Mol Cell Cardiol"},{"key":"9772_CR43","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1161\/01.ATV.0000094235.78783.D1","volume":"23","author":"S Jesmin","year":"2003","unstructured":"Jesmin S, Sakuma I, Hattori Y, Kitabatake A (2003) Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol 23:2021\u20132026","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9772_CR44","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.1971.03180230027005","volume":"215","author":"T Gorden","year":"1971","unstructured":"Gorden T, Kannel WB (1971) Premature mortality from coronary heart disease. The Framingham study. JAMA 215:1617\u20131625","journal-title":"JAMA"},{"key":"9772_CR45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1001\/archinte.1992.00400170085016","volume":"152","author":"E Grossman","year":"1992","unstructured":"Grossman E, Shemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T (1992) Left ventricular mass in diabetes. Arch Int Med 152:5","journal-title":"Arch Int Med"},{"key":"9772_CR46","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1006\/jmcc.1998.0721","volume":"30","author":"Y Sun","year":"1995","unstructured":"Sun Y, Zhang JQ, Zhang J, Ramires FJ (1995) Angiotensin II, transforming growth factor-\u03b21 and repair in the infarcted heart. J Mol Cell Cardiol 30:1559\u20131569","journal-title":"J Mol Cell Cardiol"},{"key":"9772_CR47","first-page":"772","volume":"20","author":"JFM Smits","year":"1992","unstructured":"Smits JFM, Krimpen C, Schoemaker RG, Cleutjens JPM, Daemen MJAP (1992) Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 20:772\u2013778","journal-title":"J Cardiovasc Pharmacol"},{"key":"9772_CR48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(83)90438-7","volume":"94","author":"S Funakawa","year":"1983","unstructured":"Funakawa S (1983) Renin angiotensin system and prostacyclin biosynthesis in STZ diabetic rats. Eur J Pharmacl 94:27\u201333","journal-title":"Eur J Pharmacl"},{"issue":"5","key":"9772_CR49","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1586\/14779072.4.5.615","volume":"4","author":"M Goebel","year":"2006","unstructured":"Goebel M, Clemenz M, Unger T (2006) Effective treatment of hypertension by AT 1 receptor antagonism: the past and future of telmisartan. Expert Rev Cardiovasc Ther 4(5):615\u2013620","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"9772_CR50","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/0024-3205(79)90200-5","volume":"25","author":"JJ Savarese","year":"1979","unstructured":"Savarese JJ, Berkowitz BA (1979) Beta adrenergic receptors decrease in diabetic rat hearts. Life Sci 25:2075\u20132078","journal-title":"Life Sci"},{"key":"9772_CR51","first-page":"431","volume-title":"Handbook of hypertension","author":"CM Ferrario","year":"1986","unstructured":"Ferrario CM, Ueno Y, Diz DJ, Bannes KL (1986) The renin-angiotensin system: physiological actions on the central nervous system. In: Zanchetti A, Tarazi C (eds) Handbook of hypertension, vol. 8. Elsevier Science Publishers, Amsterdam, the Netherlands, pp 431\u2013454"},{"key":"9772_CR52","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.HYP.27.6.1284","volume":"27","author":"DR Oliveira","year":"1996","unstructured":"Oliveira DR, Santos RA, Santos GF, Khosla MC, Campagnole-Santos MJ (1996) Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension 27:1284\u20131290","journal-title":"Hypertension"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-008-9772-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11010-008-9772-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-008-9772-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T02:11:22Z","timestamp":1559355082000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11010-008-9772-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,19]]},"references-count":52,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["9772"],"URL":"https:\/\/doi.org\/10.1007\/s11010-008-9772-y","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,19]]}}}